These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29739080)

  • 21. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
    Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
    Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
    Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
    Zhao D; Jiang JQ; Lin L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1173-1178. PubMed ID: 31418375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
    Ho PJ; Spencer A; Mollee P; Bryant CE; Enjeti AK; Horvath N; Butcher BE; Trotman J; Gibbs S; Joshua DE
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):543-552.e1. PubMed ID: 38702217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of serum-free light-chain levels with markers of renal function.
    Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
    Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
    Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
    BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
    Holzhey T; Pönisch W; Wang SY; Holzvogt M; Holzvogt B; Andrea M; Zehrfeld T; Hammerschmidt D; Hoffmann FA; Becker C; Schwarzer A; Schwarz M; Schönfelder-Fricke U; Edelmann T; Braunert L; Franke GN; Jentzsch M; Schwind S; Bill M; Grimm J; Remane Y; Platzbecker U; Scholz M
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2349-2359. PubMed ID: 33433659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
    Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
    Dejoie T; Corre J; Caillon H; Hulin C; Perrot A; Caillot D; Boyle E; Chretien ML; Fontan J; Belhadj K; Brechignac S; Decaux O; Voillat L; Rodon P; Fitoussi O; Araujo C; Benboubker L; Fontan C; Tiab M; Godmer P; Luycx O; Allangba O; Pignon JM; Fuzibet JG; Legros L; Stoppa AM; Dib M; Pegourie B; Orsini-Piocelle F; Karlin L; Arnulf B; Roussel M; Garderet L; Mohty M; Meuleman N; Doyen C; Lenain P; Macro M; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H
    Blood; 2016 Dec; 128(25):2941-2948. PubMed ID: 27729323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
    Heyne N; Denecke B; Guthoff M; Oehrlein K; Kanz L; Häring HU; Weisel KC
    Ann Hematol; 2012 May; 91(5):729-735. PubMed ID: 22170517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency.
    Park JW; Kim YK; Bae EH; Ma SK; Kim SW
    Clin Biochem; 2012 Jul; 45(10-11):740-4. PubMed ID: 22503879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The significance of serum IgD quantitation for evaluation of clinical efficacy in IgD multiple myeloma].
    He J; Zhang H; Jiang H; Zeng T; Chang H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):288-91. PubMed ID: 27093990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma.
    Pika T; Minarik J; Schneiderka P; Budikova M; Langova K; Lochman P; Bacovsky J; Farbiakova V; Scudla V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Jun; 152(1):61-4. PubMed ID: 18795076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L; Tian Z; Fang Q
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
    Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
    Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of immunoglobulin heavy/light chain detection on the minimal residual disease monitoring in IgG multiple myeloma patients].
    Zhang H; Zhou L; Li R; He J; Peng Z; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):95-8. PubMed ID: 25778881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia.
    Yegin ZA; Ozkurt ZN; Yağci M
    Eur J Haematol; 2010 May; 84(5):406-11. PubMed ID: 20059535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.